ECO Animal Health Group
EAH · AIM · Health Care · mcap £65m · 95.5p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 08 Oct 26 | Holding | Holding(s) in Company | |
| 17 Sep 26 | USDA-CVB approves ECOVAXXIN® MS field safety data
Milestone advances poultry vaccine towards US marketing authorisation |
+1.6% | |
| 11 Sep 26 | Share Awards to Executive Directors
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that on 9 September 2026, nomin |
−6.8% | |
| 08 Sep 26 | Routine | Result of AGM | |
| 08 Sep 26 | Board change | Didier Branellec appointed Non-Executive Director
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces the appointment of Dr. |
+1.5% |
| 19 Aug 26 | Board change | CEO and CFO Exercise of Options and RPT
CEO and CFO Exercise of Share Options and Director/PDMR Shareholdings |
+0.0% |
| 12 Aug 26 | Exclusive in-licensing agreement with Vaxinano
Exclusive in-licensing agreement with Vaxinano for sheep vaccine candidate against toxoplasmosis |
+5.7% | |
| 05 Aug 26 | Routine | Posting of Annual Report and Notice of AGM | |
| 28 Jul 26 | Holding | Holding(s) in Company | |
| 16 Jul 26 | Director dealing | Director/PDMR Shareholding: CEO Share Purchase | |
| 15 Jul 26 | Results | Results for the year ended 31 March 2026
Results for the year ended 31 March 2026 |
+2.9% |
| 13 Jul 26 | Routine | Notice of Results | |
| 02 Jul 26 | EU launch of ECOVAXXIN® MS
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company marketing and developing branded veterinary products to improve livestock productivity and welfare, announces the commercial launch of ECOVAX |
+3.2% | |
| 04 Jun 26 | Renewal of revolving credit facility
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that it has renewed its committed |
+0.0% | |
| 14 Apr 26 | Appointment of Head of Business Development
Dr Andrew Winder to identify strategic growth opportunities for ECO's R&D pipeline |
+5.3% | |
| 31 Mar 26 | Board change | Directorate Change
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Frank Armstrong has informed |
−1.5% |
| 19 Mar 26 | Trading update | Full Year Trading Update
Continued strong momentum in H2 with improved margins outperforming market expectations |
+6.2% |
| 11 Mar 26 | ECOVAXXIN® MG favourable USDA safety assessment
Assessment represents a significant milestone towards US marketing authorisation |
+4.2% | |
| 05 Mar 26 | Routine | Block Listing Return | |
| 26 Feb 26 | EU launch plans for ECOVAXXIN® MS
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, provides an update on its commercial launch |
+4.9% | |
| 19 Jan 26 | Holding | Holding(s) in Company | |
| 22 Dec 25 | ECOVAXXIN® MS EU marketing authorisation granted
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the European Commission has |
+6.2% | |
| 18 Dec 25 | Exercise of Share Options by Director
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Christopher Wilks, Chief Fin |
−4.2% | |
| 04 Dec 25 | Director dealing | Director/PDMR Shareholding | |
| 01 Dec 25 | Results | Results for the six months ended 30 September 2025
Results for the six months ended 30 September 2025 |
+4.3% |
| 20 Nov 25 | Routine | Notice of Results | |
| 20 Nov 25 | Routine | Notice of Results | |
| 10 Nov 25 | EMA Positive Opinion Received for ECOVAXXIN® MS
EMA Positive Opinion Received for ECOVAXXIN® MS poultry vaccine |
+7.4% |
Company filings. Not investment advice.